182 related articles for article (PubMed ID: 28474741)
1. Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
Smolders EJ; Colbers A; de Kanter CTMM; Velthoven-Graafland K; Wolberink LT; van Ewijk-Beneken Kolmer N; Drenth JPH; Aarnoutse RE; Tack CJ; Burger DM
Br J Clin Pharmacol; 2017 Oct; 83(10):2225-2234. PubMed ID: 28474741
[TBL] [Abstract][Full Text] [Related]
2. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
3. The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics.
Wen J; Zeng M; Liu Z; Zhou H; Xu H; Huang M; Zhang W
J Pharmacol Sci; 2019 Jan; 139(1):37-41. PubMed ID: 30538075
[TBL] [Abstract][Full Text] [Related]
4. A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study.
Chung H; Oh J; Yoon SH; Yu KS; Cho JY; Chung JY
PLoS One; 2018; 13(1):e0191258. PubMed ID: 29342199
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium-glucose cotransporter 2 inhibitor and metformin in healthy subjects.
Kim B; Huh KY; Hwang JG; Nah J; Huh W; Cho JM; Jang IJ; Yu KS; Kim Y; Lee S
Br J Clin Pharmacol; 2023 Apr; 89(4):1462-1470. PubMed ID: 36422809
[TBL] [Abstract][Full Text] [Related]
6. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
7. A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers.
Noh YH; Lim HS; Jung JA; Jin SJ; Kim MJ; Kim YH; Park HJ; Bae KS
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):605-13. PubMed ID: 22762856
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects.
Cho HY; Yoon H; Lim YC; Lee YB
Int J Clin Pharmacol Ther; 2009 Dec; 47(12):770-9. PubMed ID: 19954716
[TBL] [Abstract][Full Text] [Related]
9. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.
Ding Y; Jia Y; Song Y; Lu C; Li Y; Chen M; Wang M; Wen A
Eur J Clin Pharmacol; 2014 Feb; 70(2):141-6. PubMed ID: 24170325
[TBL] [Abstract][Full Text] [Related]
10. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
[TBL] [Abstract][Full Text] [Related]
11. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
[TBL] [Abstract][Full Text] [Related]
12. Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects.
Yi L; Zhang H; Zhang JW; You XM; Ning ZQ; Yu J; Qian LF; Miao LY
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):934-941. PubMed ID: 30809967
[TBL] [Abstract][Full Text] [Related]
13. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics.
Kim A; Chung I; Yoon SH; Yu KS; Lim KS; Cho JY; Lee H; Jang IJ; Chung JY
Drug Metab Dispos; 2014 Jul; 42(7):1174-9. PubMed ID: 24764147
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.
Rhee SJ; Choi Y; Lee S; Oh J; Kim SJ; Yoon SH; Cho JY; Yu KS
Drug Des Devel Ther; 2016; 10():2525-34. PubMed ID: 27570447
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
Jeong SI; Kim Y; Nah JJ; Huh W; Jang IJ; Hwang JG; Lee S
Br J Clin Pharmacol; 2023 Jun; 89(6):1780-1788. PubMed ID: 36496349
[TBL] [Abstract][Full Text] [Related]
16. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers.
Liu G; Wen J; Guo D; Wang Z; Hu X; Tang J; Liu Z; Zhou H; Zhang W
J Pharmacol Sci; 2016 Dec; 132(4):244-248. PubMed ID: 27245553
[TBL] [Abstract][Full Text] [Related]
17. Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers.
Garza-Ocañas L; González-Canudas J; Tamez-de la O E; Badillo-Castañeda C; Gómez-Meza MV; Romero-Antonio Y; Molina-Pérez A; Amador-Hernández AG
Adv Ther; 2019 Feb; 36(2):407-415. PubMed ID: 30565181
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus
Bhatia A; Tawade S; Mastim M; Kitabi EN; Gopalakrishnan M; Shah M; Yeshamaina S; Gobburu J; Sahib M; Thakur D; Prasanna Kumar KM
Acta Diabetol; 2018 May; 55(5):461-468. PubMed ID: 29453671
[TBL] [Abstract][Full Text] [Related]
19. Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.
Chevalier C; Perrimond-Dauchy S; Dubourg J; Fouqueray P; Bolze S
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):725-733. PubMed ID: 32860624
[TBL] [Abstract][Full Text] [Related]
20. Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Adv Ther; 2015 May; 32(5):404-17. PubMed ID: 25975816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
